PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2D325F423K4569520123!imipenem-cilastatin 500 MG VLS — Fresenius Kabi, LLC

Fresenius Kabi, LLC holds $98.3M across 1,575 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 2 related awards under parent SPE2D020D0009. PoP ended Sep 22, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Fresenius Kabi, LLC

Recipient

Sep 22, 2025

PoP end

$275K

Obligated

$275K

Potential

325411

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Fresenius Kabi, LLC — $90

Contract facts

Federal

Contract numberSPE2D325F423K

Also listed asSPE2D020D0009-SPE2D325F423K

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentFresenius Kabi, LLC

CAGE57KZ6

UEIC2TRNWNQKMD6

NAICS325411

No full NAICS 325411 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2D020D0009

Place of performanceLAKE ZURICH IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 17, 2025

PoP end (current)Sep 22, 2025

Obligated$275K

Current value$275K

Potential value$275K

4569520123!IMIPENEM-CILASTATIN 500 MG VLS is a federal award for Dla Troop Support held by Fresenius Kabi, LLC. Estimated value $275K ($275K obligated). Current period of performance ends Sep 22, 2025. Place of performance: LAKE ZURICH IL.

4569520123!IMIPENEM-CILASTATIN 500 MG VLS

Recompete timing

Public

● Past PoP end (333 days ago)

Current PoP ended Sep 22, 2025 (333 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Fresenius Kabi, LLC — $98.3M obligated across 1,575 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($98.3M) · all agencies

Department of Health and Human Services (HHS)$94.1M · 96%Department of Defense (DOD)$4.2M · 4%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D025F0535

8511525788!OTHER MEDICAL

$1.4M

Aug 31, 2026

75A50326F80006

ATROPINE 0.4MGML X 20ML SOLN. FOR INJ., MULTI-DOSE VIALS 8MG AND MIDAZOLAM SOLN. FOR INJ.,…

$7.9M

Jul 29, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2D325F423K?

SPE2D325F423K (4569520123!imipenem-cilastatin 500 MG VLS) is a Dla Troop Support award with a potential value of $275K, currently held by Fresenius Kabi, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2D325F423K?

Dla Troop Support awarded SPE2D325F423K to Fresenius Kabi, LLC (potential $275K).

Who is the incumbent on SPE2D325F423K?

Fresenius Kabi, LLC is the incumbent with $98.3M across 1575 related awards in SCOUT’s public footprint. The current period of performance ends Sep 22, 2025.

When does Fresenius Kabi, LLC’s SPE2D325F423K come up for recompete?

SCOUT tracks a period-of-performance end of Sep 22, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 18, 2026 · refreshed monthlyLatest procurement action Sep 17, 2025